Compare BBGI & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBGI | MRKR |
|---|---|---|
| Founded | 1961 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 19.5M |
| IPO Year | 1999 | 2010 |
| Metric | BBGI | MRKR |
|---|---|---|
| Price | $8.80 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.87 |
| AVG Volume (30 Days) | 29.3K | ★ 81.4K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ 48.01 | N/A |
| Revenue | ★ $232,179,463.00 | N/A |
| Revenue This Year | N/A | $19.61 |
| Revenue Next Year | $0.47 | $375.85 |
| P/E Ratio | $0.18 | ★ N/A |
| Revenue Growth | ★ 69.89 | N/A |
| 52 Week Low | $3.14 | $0.84 |
| 52 Week High | $29.30 | $2.46 |
| Indicator | BBGI | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 22.56 | 49.50 |
| Support Level | $3.50 | N/A |
| Resistance Level | $24.70 | $1.34 |
| Average True Range (ATR) | 1.29 | 0.08 |
| MACD | -0.14 | -0.00 |
| Stochastic Oscillator | 12.98 | 59.38 |
Beasley Broadcast Group Inc is a multi-platform media company whose primary business is operating radio stations throughout the United States. The company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. It owns and operates stations in the following markets: Atlanta, GA; Augusta, GA; Boston, MA; Charlotte, NC; Detroit, MI; Fayetteville, NC; Fort Myers-Naples, FL; Las Vegas, NV; Middlesex, NJ; Monmouth, NJ; Morristown, NJ; Philadelphia, PA; Tampa-Saint Petersburg, FL; and Wilmington, DE. The company operates in two segments: Audio, which generates the maximum revenue, and Digital.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).